Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes

Open access
Hermansen, Kjeld, Davies, Melanie, Derezinski, Taudeusz, Martinez Ravn, Gabrielle, Clauson, Per, Home, Philip, on behalf of the Levemir Treat-to-Target Study Group · 2006 · Diabetes Care

Abstract

OBJECTIVE—To assess efficacy and tolerability of insulin detemir or NPH insulin added to oral therapy for type 2 diabetes in a treat-to-target titration protocol. RESEARCH DESIGN AND METHODS—Individuals (n = 476) with HbA1c (A1C) 7.5–10.0% were randomized to addition of twice-daily insulin detemir or NPH insulin in a parallel-group, multicenter trial. Over 24 weeks, insulin doses were titrated toward prebreakfast and predinner plasma glucose targets of ≤6.0 mmol/l (≤108 mg/dl). Outcomes assessed included A1C, percentage achieving A1C ≤7.0%, risk of hypoglycemia, and body weight. RESULTS—At 24 weeks, A1C had decreased by 1.8 and 1.9% (from 8.6 to 6.8 and from 8.5 to 6.6%) for detemir and NPH, respectively (NS). In both groups, 70% of participants achieved an A1C ≤7.0%, but the proportion achieving this without hypoglycemia was higher with insulin detemir than with NPH insulin (26 vs. 16%, P = 0.008). Compared with NPH insulin, the risk for all hypoglycemia with insulin detemir was reduced by 47% (P < 0.001) and nocturnal hypoglycemia by 55% (P < 0.001). Mean weight gain was 1.2 kg with insulin detemir and 2.8 kg with NPH insulin (P < 0.001), and the difference in baseline-adjusted final weight was −1.58 (P < 0.001). CONCLUSIONS—Addition of basal insulin to oral drug therapy in people with suboptimal control of type 2 diabetes achieves guideline-recommended A1C values in most people with aggressive titration. Insulin detemir compared with NPH insulin achieves this with reduced hypoglycemia and less weight gain.

Overview

Integrity signals

Registry

Crossref · 10.2337/dc05-1365

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 36 references

Research works printed but not linked: 1

  1. Raslova K, Bogoev M, Raz I, Leth G, Gall MA, Hancu N: Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes Diabetes Res Clin Pract 66:193–201, 2004 · DOI · Paper page

Cited by

See all 627

Metadata

Authors
Hermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group
Affiliations
  • Aarhus University Hospital (DK)
  • Leicester Royal Infirmary (GB)
  • Out-Patient Clinic, NZOZ Eskulap, Gniewkowo, Poland
  • Out-Patient Clinic, Novo Nordisk, Bagsværd, Denmark
  • Novo Nordisk (Denmark) (DK)
  • Newcastle University (GB)
Venue
Diabetes Care
Published
2006-06-01
Volume
29
Issue
6
Pages
1269-1274
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2149194615
Cited by
627
References
36
Citations by year
2026: 3 · 2025: 4 · 2024: 3 · 2023: 6 · 2022: 10 · 2021: 11 · 2020: 13 · 2019: 11 · 2018: 16 · 2017: 15 · 2016: 24 · 2015: 31 · 2014: 44 · 2013: 59 · 2012: 55
FWCI
48.57
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
  • Leicester Research Archive (University of Leicester) (submittedVersion)
  • Newcastle University ePrints (Newcastle Univesity)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
insulin detemir, NPH insulin, basal insulin, type 2 diabetes, insulin-naive patients, oral glucose-lowering agents, adjunctive therapy, glycemic control, HbA1c, hypoglycemia, nocturnal hypoglycemia, weight gain
MeSH terms
Insulin Detemir, Administration, Oral, Adult, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Insulin, Isophane, Weight Gain, Body Mass Index, Insulin, Long-Acting

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. https://app.cochat.ai/papers/10.2337/dc05-1365
The paper
Hermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group. (2006). A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. https://doi.org/10.2337/dc05-1365

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.